KLRA

KLRA remains in a pronounced intermediate downtrend, trading below all major moving averages, and has just bounced off extreme oversold levels. Medium-term structure stays bearish, and without reclaiming the 9-day and 20-day EMA cluster overhead, any relief rally is likely to fade. Optimal execution is to defer aggressive selling until price retests and is rejected at resistance zones around $16.40–$17.50.

• ↑Phase 2 ribupatide trial delivered >12.1% average weight loss
• ↑$1.17B cash runway supports operations into mid-2028
• ↓Q2 2026 net loss widened to $111.3M from $28.9M YoY